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PHAGE	THERAPY:	THE	CURE	FOR	SUPERBUGS
Nowadays, antibiotic-resistant bacteria or superbugs, are one of the biggest problems in the world. The humankind is heading to a
“post-antibiotic” era in which common infections and minor injuries can kill again.[1,2] So, as fewer antibiotics are being discovered,
suitable alternatives need to be found. The use of lytic bacteriophages, in a process known as phage therapy, is re-emerging as a as
potential therapeutic solution for tackling superbugs.
§ Bacteriophages or phages are viruses that infect bacteria and are harmless to eukaryotic cells.
§ Phages constitute the largest biomass on Earth.
§ They bind to specific receptors and incorporate their genetic material into the bacterial host cell
by either a lytic or lysogenic cycle.
Antibiotic and phage therapy are antibacterial treatments that either inhibit bacteria or lysate them. Depending on the situation, phage therapy can be an alternative to antibiotics or
either applied together as synergistic therapies. Despite the great number of advantages that phage therapy has [Table 1], there are also certain limitations.[7]
Phage Biology basics
Ø Lack of studies and clinical data.
Ø Phages are self-limiting and they will only persist as long as their targeted pathogen is
present.
Ø Highly immunogenic and rapid clearance from the bloodstream.
Ø Narrow host range:
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Phage therapy involves the use of lytic phages which specifically kill pathogenic bacteria at the site
of the infection. There are many essential steps[5,6] involved in the therapy [Figure 1] and two typical
models of phage choice that can be administered in an oral, intravenous or topic way:
Ø Custom-designed preparations: the infecting pathogenic bacteria are isolated from the patient
and tested against a well characterized phage collection. It is complex and time-consuming.
Ø Mainstream-production preparations: phage cocktails (multiple phages with an in vitro efficacy
against the target pathogen) are used. The cocktails display a broader spectrum of activity. The
first therapeutic phage preparation available for a commercial use will probably be based on
this approach.
The aim of this review is to determine whether
phage therapy can be used against superbugs in
order to fight a wide-range of human diseases.
FIGURE 1.- Essential steps involved in phage therapy. In summary, phage isolation is done together with
a host-range determination. Purification steps are also essential to avoid carrying toxins. This is followed
by an in vitro characterization in association with a further host-range determination and an in silico
characterization. For promising phages, in vivo characterization comes next. Finally, regulatory
requirements are needed to implement the therapy on a large-scale. [Source: modified from (6) and
created with Microsoft® PowerPoint]
BACTERIOPHAGES	AS	ANTIBACTERIAL	AGENTS
TIMELINE	OF	PHAGE	THERAPY	HISTORY	[3,4]	
§ Loss of effectiveness Improvementswith phage cocktails are being tested.
§ Preliminar selection of the phages PCR or 16s rRNA sequencing facilitate the rapid
and accurate selection of phages.
§ Phage therapeutic preparations are only available in some countries: Georgia, Poland
or Russia.
§ The European Medicine agency considers bacteriophages as phage therapy
medicinal products (PTMPs).[8]
§ Phage therapy has been used publicly for many years and consequently the
technique itself could not be patented.
§ Difficulty in obtaining funding for research or clinical trials.
§ Phagoburn is the first European big clinical trial in Phase I-II.
TABLE	1.- Comparison between antibiotic therapy and phage therapy.	
ENZYBIOTICS	[9] - Combination between antibiotics and purified enzymes- Lysins, other natural or synthetic enzymes are used
- Phages are genetically modified and adapted to a purpose
- Increasing of bacteriophages natural features
- Ultimate goal: to create completely synthetic phages
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Limitations of	phage therapy
The therapy success depends on the phage densities reached on the target so as to achieve the
desired levels of bacterial eradication.
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The use of phages as antibacterial agents is re-emerging as a solution for overcoming the antibiotic resistance worldwide threat. Further studies are needed for a better understanding on
the therapy and its relation with the human host. Moreover, progress in the regulation framework is required before implementing the therapy on a large scale. However, there are still
many difficulties and a negative public perception against viruses and its therapeutic use. The available data suggest that novel approaches, such as enzybiotics or genetically modified
phages, are promising solutions for improving the future of phage therapy.
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